{"id":"NCT05543187","sponsor":"Takeda","briefTitle":"A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)","officialTitle":"An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-01-10","primaryCompletion":"2023-09-04","completion":"2025-07-22","firstPosted":"2022-09-16","resultsPosted":"2024-09-24","lastUpdate":"2025-08-22"},"enrollment":5,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Progressive Familial Intrahepatic Cholestasis (PFIC)"],"interventions":[{"type":"DRUG","name":"TAK-625","otherNames":["Maralixibat chloride"]}],"arms":[{"label":"TAK-625, Primary cohort","type":"EXPERIMENTAL"},{"label":"TAK-625, Supplemental cohort","type":"EXPERIMENTAL"}],"summary":"The main aim of the study is to check if TAK-625 improves symptoms of Progressive Familial Intrahepatic Cholestasis (PFIC), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future.\n\nThe participants will be treated with TAK-625 for up to the end of study (about 34 months).\n\nParticipants will visit their study clinic 15 times from the start of study. After 15 times visits, participants will visit their study clinic every 12 weeks up to the end of study.","primaryOutcome":{"measure":"Change in the Average Morning Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) Severity Score Between Baseline and the Average of Week 15 Through Week 26","timeFrame":"Baseline to Week 15 through Week 26","effectByArm":[{"arm":"Primary Cohort: TAK-625","deltaMin":-1.514,"sd":null},{"arm":"Supplemental Cohort: TAK-625","deltaMin":-0.202,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5c64837a6d7c464c"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":3},"commonTop":["Upper respiratory tract infection","Diarrhoea","Gastroenteritis","Influenza","Auricular haematoma"]}}